Tue, Jul 29, 2014, 11:41 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Navidea Biopharmaceuticals, Inc Message Board

  • zinsinus zinsinus Mar 14, 2013 10:07 AM Flag

    UPGRADE

    target from 7 to 9
    WBB
    as per oldtimers

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • yeah we got our approval.....the problem is the shorts own this stock for an obscene amount of time.

    • We believe that today's announcement, coupled with upcoming events make NAVB a company
      with a profitable and independent future. If Lymphoseek only had potential as an ILM agent for
      breast cancer and melanoma, NAVB could be relegated to the role of a moderately profitable
      company that could easily be rolled into a larger corporation. However, the range of options
      and capabilities the company faces makes it a significant, if now nascent concern.
      Given the benefits of Lymphoseek over isosulfan blue dye or Sulfur Colloid, coupled with the
      marketing presence and strength of CAH, it is probable that Lymphoseek will quickly supersede
      both of those two agents for ILM. Consider, that in ILM for breast, melanoma, head and neck,
      and colorectal alone, Lymphoseek has the potential for sales of a half-million doses a year.
      Then there are other solid tumor cancers, such as lung or prostate, in which Lymphoseek could,
      for the first time, potentially be used as a staging agent.
      As this agent is accepted and its superior capabilities become apparent, there will be those
      physicians who will ultimately want to use it in Sentinel Lymph Node Mapping, which is a
      procedure to identify the first lymph node into which a cancer is likely to spread from the
      primary tumor. Since there currently is no FDA approved product for sentinel lymph node
      mapping, it is likely that there will be interest in using Lymphoseek for this procedure.
      Strengthening NAVB's position is the possession of two other promising agents. One of which,
      is a Phase II diagnostic for Alzheimer's Disease. NAVB has now demonstrated that it has the
      wherewithal to shepherd a diagnostic product through the FDA approval process. Any acquirer
      would need to demonstrate that it too has such a capability or incur the disapproval of a large
      segment of the public, medical community and potentially the FDA.

      • 1 Reply to laonda32
      • CAH has long been identified as the most probable acquirer of NAVB once Lymphoseek
        becomes a commercial product. By acquiring NAV 4694, NAVB has raised the acquisition
        stakes for any potential takeover. CAH has no development experience and the breadth of
        potential applications for Lymphoseek, combined with prospects for NAV 4694 and long-term
        potential for RIGScan raise the stakes for acquisition.
        WBB still uses a sum of the parts model in its valuation of NAVB. Following the FDA’s approval
        of Tilmanocept and using a fully diluted share counted of 154MM shares, we are now
        increasing our 12-month target price to $9.00. This recognizes both 2013E revenue and
        certainly earnings will not be representative of the franchise’s potential. Instead we look to
        measure the full value of NAVB by assigning an increased $5.50 value to Lymphoseek. With
        the increased partnering visibility of the global Alzheimer’s epidemic we now value AZD4694 at
        $1.10 and continue to assign a $2.40 per share value for the RIGS technology.

    • analysts have been touting this POS for 2 years and we are at 2.98 so obviously these reports and opinion are meaningless, why does everyone get so psyched about them..

 
NAVB
1.32-0.02(-1.49%)Jul 29 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.